Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki and Emmanuel Deshayes
Journal of Nuclear Medicine June 2024, 65 (6) 923-930; DOI: https://doi.org/10.2967/jnumed.123.267023
Kévin Hebert
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lore Santoro
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maeva Monnier
3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florence Castan
3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ikrame Berkane
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Assénat
4Department of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cyril Fersing
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
4Department of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France;
5IBMM, Université de Montpellier, CNRS, ENSCM, Montpellier, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauline Gélibert
6Centre Hospitalier Métropole Savoie, Chambéry, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Pouget
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Bardiès
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Olivier Kotzki
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Deshayes
1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;
2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (6)
Journal of Nuclear Medicine
Vol. 65, Issue 6
June 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
Journal of Nuclear Medicine Jun 2024, 65 (6) 923-930; DOI: 10.2967/jnumed.123.267023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
Journal of Nuclear Medicine Jun 2024, 65 (6) 923-930; DOI: 10.2967/jnumed.123.267023
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Rethinking Dosimetry: A European Perspective
  • Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Direct Correlation of Tumor Absorbed Dose with Overall Survival in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu Prostate-Specific Membrane Antigen
  • Assessment of [177Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360{degrees} Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol
  • Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions
  • MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
  • Multicycle Dosimetric Behavior and Dose-Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
  • Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
  • Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET
  • Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

Keywords

  • [177Lu]Lu-DOTATATE
  • neuroendocrine tumors
  • absorbed dose–response relationship
SNMMI

© 2025 SNMMI

Powered by HighWire